Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Antimigraine Drugs Market by Product (Drug Class/Brand) – Acute Agents [Triptans, Oral Anti-CGRPs [Ubrelvy (ubrogepant), Nurtec/Vydura (rimegepant), Qulipta (atogepant), Zavzpret (zavegepant), Other Agents [Reyvow (lasmiditan)], Others], Preventive Agents [Botox (onabotulinum toxin A), Anti-CGRP mAbs [Aimovig (erenumab), Emgality (galcanezumab), Ajovy (fremanezumab), Vyepti (eptinezumab)], Oral Anti-CGRPs, Others] and Forecast 2024-2031

$3,000.00

Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

Migraine is a common and highly disabling neurological disorder. The American Migraine Foundation estimates migraine headaches affect 38 million in US alone, and it is three times more women than men.

Migraine treatment is divided into two paradigms: acute treatment, which is taken as an abortive treatment at the onset of an attack, and prophylactic treatment, which is administered chronically to prevent new migraine attacks. Migraine treatment traditionally includes both preventive therapies, aimed at reducing attack frequency and severity, and acute therapy, for aborting attacks.

The global migraine-inhibiting drugs market research report provides market size ($million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031).

The global antimigraine drugs market segmented by product (drug class/brand) – acute agents [Triptans, Oral anti-CGRPs [Ubrelvy (ubrogepant), Nurtec/Vydura (rimegepant), Qulipta (atogepant), Zavzpret (zavegepant), other agents [Reyvow (lasmiditan)], others], preventive agents [Botox (onabotulinum toxin A), anti-CGRP mAbs [Aimovig (erenumab), Emgality (galcanezumab), Ajovy (fremanezumab), Vyepti (eptinezumab)], oral anti-CGRPs, others], and geography.

The global antimigraine drugs market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.

In addition, the global antimigraine treatment market report provides the detailed market landscape (market drivers, restraints, and opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global antimigraine drugs market and profiled in this report include AbbVie, Inc., Amgen, Inc., Amneal Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Inc., Eli Lilly and Company, H. Lundbeck A/S, Johnson & Johnson, Novartis AG, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.

DATA INCLUDED: Antimigraine Drugs Market Size, Antimigraine Drugs Market Share, Antimigraine Drugs Market Growth Rates, Antimigraine Drugs Market Trends, and Antimigraine Drugs Market Forecast to 2031

Market Data:

  • Base year for estimation: 2023
  • Actual estimates/Historical data: 2021-2031
  • Forecast period: 2024-2031
  • Market representation: Revenue in $million and CAGR % from 2024 to 2031
  • Regional scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
  • Country scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE and others.
  • Report coverage: Revenue forecast, company share, competitive landscape, growth factors, and trends
  • 15% free customization scope: Any specific or custom requirements, which is not currently within the scope of the report, will be provided as a part of customization.

Qualitative Analysis:

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Key market opportunities
  • Market size
  • Growth trends
  • Porter’s five forces analysis
  • Market attractiveness analysis
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product portfolio
    • Strategic insights
    • Recent developments

Quantitative Analysis:

  • Market size estimates and forecast for all segments
  • Regional market size estimated and forecast for major countries
  • Company financial performance
  • Competitive landscape: Company market share analysis

Please contact us for offers on individual or multiple report purchases.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation ($million, 2021-2031)
    • Forecast Estimation ($million and CAGR%, 2024-2031)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2031)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Key Questions Answered:
1. What are the factors driving and limiting this market, key success factors and challenges?
2. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?
3. How do markets perform between countries and regions?
4. What market segments are contributing to maximum share and greatest growth?
5. What are the product or procedure volumes by country and regions?

Actionable Insights Included:
1. Product portfolio matrix (Share vs. Growth)
2. Market attractiveness (Region vs. Growth)
3. Spot matrix (Product vs. Region)
4. Geographic distribution matrix (Share vs. Growth)

Antimigraine Drugs Market

1. Product (Drug Class/Brand)
1.1. Acute Agents
1.1.1. Triptans
1.1.2. Oral Anti-CGRPs [Calcitonin Gene-Related Peptide (CGRP) Antagonist]
1.1.2.1. Ubrelvy (ubrogepant)
1.1.2.2. Nurtec/Vydura (rimegepant)
1.1.2.3. Qulipta (atogepant)
1.1.2.4. Zavzpret (zavegepant) nasal spray
1.1.3. Other Acute Agents (Neurally Acting Antimigraine Agent)
1.1.3.1. Reyvow (lasmiditan)
1.1.4. Others
1.2. Preventive / Prophylactic Agents
1.2.1. Botox (Onabotulinum toxin A)
1.2.2. Anti-CGRP mAbs
1.2.2.1. Aimovig (erenumab)
1.2.2.2. Emgality (galcanezumab)
1.2.2.3. Ajovy (fremanezumab)
1.2.2.4. Vyepti (eptinezumab)
1.2.3. Oral Anti-CGRPs
1.2.4. Others

2. Geography
2.1. North America (U.S., Canada)
2.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.3. Asia Pacific (Japan, China, India, Rest of APAC)
2.4. Latin America (Brazil, Mexico, Rest of LA)
2.5. Rest of the World

3. Company Profiles
3.1. AbbVie, Inc.
3.2. Amgen, Inc.
3.3. Biohaven Pharmaceuticals, Inc.
3.4. Eli Lilly and Company
3.5. GSK plc (GlaxoSmithKline)
3.6. H. Lundbeck A/S
3.7. Johnson & Johnson
3.8. Merck & Co., Inc.
3.9. Novartis AG
3.10. Pfizer, Inc.
3.11. Teva Pharmaceutical Industries Ltd.

    Request ToC / Sample Report

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com